| Literature DB >> 36232778 |
Mingmei Ji1, Jiahui Zhong2, Runzhe Xue1, Wenhua Su1, Yawei Kong1, Yiyan Fei1, Jiong Ma1,2,3, Yulan Wang4, Lan Mi1,2.
Abstract
Cervical cancer has high morbidity and mortality rates, affecting hundreds of thousands of women worldwide and requiring more accurate screening for early intervention and follow-up treatment. Cytology is the current dominant clinical screening approach, and though it has been used for decades, it has unsatisfactory sensitivity and specificity. In this work, fluorescence lifetime imaging microscopy (FLIM) was used for the imaging of exfoliated cervical cells in which an endogenous coenzyme involved in metabolism, namely, reduced nicotinamide adenine dinucleotide (phosphate) [NAD(P)H], was detected to evaluate the metabolic status of cells. FLIM images from 71 participants were analyzed by the unsupervised machine learning method to build a prediction model for cervical cancer risk. The FLIM method combined with unsupervised machine learning (FLIM-ML) had a sensitivity and specificity of 90.9% and 100%, respectively, significantly higher than those of the cytology approach. One cancer recurrence case was predicted as high-risk several months earlier using this method as compared to using current clinical methods, implying that FLIM-ML may be very helpful for follow-up cancer care. This study illustrates the clinical applicability of FLIM-ML as a detection method for cervical cancer screening and a convenient tool for follow-up cancer care.Entities:
Keywords: NAD(P)H; cervical cancer; fluorescence lifetime imaging microscopy; non-invasive screening; unsupervised machine learning
Mesh:
Substances:
Year: 2022 PMID: 36232778 PMCID: PMC9570424 DOI: 10.3390/ijms231911476
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Typical FLIM images of unstained exfoliated cervical cells from four participants (each column is from one person); (a–d) are from two cervical cancer patients and (e–h) are from two normal cases where the autofluorescence is from the intracellular NAD(P)H; t means the mean fluorescence lifetime of NAD(P)H; and a2 means the contribution of protein-bound NAD(P)H. Scale bar: 20 µm.
Figure 2Statistical FLIM data of exfoliated cervical cells from the CC (n = 11), CINII/III (n = 7), benign (n = 18), and normal (n = 23) groups. (a) The average fluorescence lifetime (t) of NAD(P)H of cervical cells based on the peak values of the FLIM distribution curves. (b) The protein-bound NAD(P)H proportion (a2) of cervical cells based on the peak values of the FLIM distribution curves. Each column represents one participant, and each circle represents one FLIM image data.
Distribution of the 71 participants in the training dataset and the validation dataset based on their clinical diagnosis.
| Clinical Diagnosis | Training Dataset | Validation Dataset |
|---|---|---|
| Cervical cancer | 5 | 6 |
| CINII/III | 4 | 3 |
| Benign | 0 | 18 |
| Normal | 14 | 9 |
| Follow-up | 0 | 12 |
| Total number | 23 | 48 |
Figure 3Flow chart of the FLIM-ML model for the prediction of high risk of cervical cancer.
Figure 4t-SNE projection of feature data extracted from three input images of the training dataset and the preserved different total variances of the data. Each point represents one FLIM image data. Blue points are from 217 FLIM images of the normal group and red points are from 151 FLIM images of cervical cancer or CINII/III groups.
Results of clustering of cell images in the training dataset.
| Input Images | Group | Cluster 1 | Cluster 2 |
|---|---|---|---|
| CC/CINII-III | 114/151 (75.5%) | 37/151 (24.5%) | |
| Normal | 5/217 (2.3%) | 212/217 (97.7%) | |
| CC/CINII-III | 114/151 (75.5%) | 37/151 (24.5%) | |
| Normal | 0/217 (0%) | 217/217 (100%) | |
| CC/CINII-III | 114/151 (75.5%) | 37/151 (24.5%) | |
| Normal | 0/217 (0%) | 217/217 (100%) |
Percentage of abnormal images in the validation group and the results of FLIM combined with machine learning. For comparison, the results of the LBC test of the patients are also listed.
| Patient No. | Percentage of Abnormal Images | FLIM-ML | LBC Test | ||
|---|---|---|---|---|---|
| CC-2 (stage IB3) | 100.0 | 100.0 | 100.0 | + | + |
| CC-4 (stage IB2) | 100.0 | 100.0 | 95.6 | + | + |
| CC-6 (stage IIB) | 100.0 | 100.0 | 100.0 | + | + |
| CC-8 (stage IA1) | 2.5 | 0.0 | 0.0 | −(FN) | + |
| CC-10 (stage IIA1) | 100.0 | 100.0 | 100.0 | + | + |
| CC-11 (stage IIB) | 73.7 | 100.0 | 89.5 | + | + |
| CINII-2 | 83.3 | 83.3 | 58.3 | + | −(FN) |
| CINII-4 | 50.0 | 80.0 | 50.0 | + | + |
| CINII-6 | 78.3 | 91.3 | 78.3 | + | + |
| Benign-1 | 0.0 | 0.0 | 0.0 | − | − |
| Benign-2 | 0.0 | 0.0 | 0.0 | − | − |
| Benign-3 | 8.3 | 8.3 | 8.3 | − | − |
| Benign-4 | 4.5 | 0.0 | 0.0 | − | − |
| Benign-5 | 0.0 | 0.0 | 0.0 | − | − |
| Benign-6 | 0.0 | 0.0 | 0.0 | − | − |
| Benign-7 | 45.5 | 0.0 | 0.0 | − | − |
| Benign-8 | 73.3 | 40.0 | 40.0 | − | − |
| Benign-9 | 0.0 | 0.0 | 0.0 | − | − |
| Benign-10 | 0.0 | 0.0 | 0.0 | − | − |
| Benign-11 | 36.4 | 9.1 | 9.1 | − | − |
| Benign-12 | 0.0 | 0.0 | 0.0 | − | − |
| Benign-13 | 0.0 | 11.1 | 0.0 | − | − |
| Benign-14 | 20.0 | 20.0 | 20.0 | − | − |
| Benign-15 | 54.5 | 9.1 | 0.0 | − | − |
| Benign-16 | 0.0 | 0.0 | 0.0 | − | − |
| Benign-17 | 36.4 | 45.5 | 36.4 | − | − |
| Benign-18 | 58.3 | 0.0 | 0.0 | − | +(FP) |
| Normal-15 | 0.0 | 0.0 | 0.0 | − | − |
| Normal-16 | 0.0 | 0.0 | 0.0 | − | − |
| Normal-17 | 0.0 | 0.0 | 0.0 | − | − |
| Normal-18 | 0.0 | 0.0 | 0.0 | − | − |
| Normal-19 | 50.0 | 0.0 | 15.4 | − | +(FP) |
| Normal-20 | 0.0 | 23.1 | 0.0 | − | +(FP) |
| Normal-21 | 36.4 | 0.0 | 0.0 | − | +(FP) |
| Normal-22 | 0.0 | 0.0 | 0.0 | − | +(FP) |
| Normal-23 | 0.0 | 0.0 | 0.0 | − | − |
| Follow-up-1 | 10.0 | 0.0 | 0.0 | − | − |
| Follow-up-2 | 0.0 | 0.0 | 0.0 | − | − |
| Follow-up-3 | 10.0 | 0.0 | 0.0 | − | − |
| Follow-up-4 | 13.3 | 13.3 | 13.3 | − | − |
| Follow-up-5 (VINII-III) | 85.0 | 100.0 | 70.0 | + | + |
| Follow-up-6 | 0.0 | 37.5 | 0.0 | − | − |
| Follow-up-7 (VAINIII) | 100.0 | 88.0 | 76.0 | + | −(FN) |
| Follow-up-8 | 5.0 | 55.0 | 10.0 | − | − |
| Follow-up-9 | 0.0 | 45.0 | 10.0 | − | − |
| Follow-up-10 | 5.0 | 0.0 | 0.0 | − | − |
| Follow-up-11 | 15.0 | 40.0 | 15.0 | − | − |
| Follow-up-12 | 5.0 | 5.0 | 0.0 | − | − |
FP: false positive; FN: false negative.
Figure 5ROC curve and AUC for the three different input images.
Figure 6Confusion matrixes of the two methods: (a) LBC test; (b) FLIM-ML method.
Sensitivity and specificity of the LBC test and FLIM-ML method.
| Method | Sensitivity (%) | Specificity (%) |
|---|---|---|
| LBC | 81.8 | 86.5 |
| FLIM-ML | 90.9 | 100 |
Figure 7Results of three follow-up patients. (a) FLIM t images of the three patients. LBC test; (b) the results of the LBC test and FLIM-ML method and the clinical diagnosis. Follow-up-7 was predicted as high risk by FLIM-ML at the first follow-up visit but was judged normal by the current clinical methods. The cancer recurrence of Follow-up-7 was not clinically found until the second visit eight months later.